RN Mobile Menu

Search form


Amy Reyes

Amy Reyes

Amy Reyes is editor of Rheumatology Network.  She is an experienced journalist and science writer who has worked as a staff writer for Mayo Clinic, the University of Michigan and Duke University Medical Center, where she specialized in covering advances in basic and clinical science in a multitude of disciplines.

Posts by Author


The FDA has nixed Eli Lilly's and Inctye's application for baricitinib in its current form asking for additional safety and clinical data.

(Systemic Lupus Erythematosus  ©farland80/Shutterstock.com)

Researchers suggest rheumatologists screen systemic lupus erythematosus patients for stroke risk — during the first visit.


Researchers are suggesting the adoption of triple therapy as a first-line treatment after RA patients fail methotrexate monotherapy.

Pain (©UEUAphoto/Shutterstock.com)

Kinesiophobia, or the fear of movement, may keep knee osteoarthritis patients from physical therapy and by consequence, recovery.

Chiropractic care. (©AlbinaGlisic/Shutterstock.com)

Despite clinical evidence, patients are seeking chiropractic care for back pain. This study shows there may be some merit in the practice.

Apps (©Chinnapong/Shutterstock.com)

Not all mobile apps are the same and it’s important to understand the function and quality of mobile apps for monitoring disease activity, researchers write in a review of the leading apps for RA.

Apps (©YmgermanShutterstock.com)

In this slideshow, we highlight the best of RA mobile apps that are designed to track disease activity. The list, a total of 19 apps, is based on a scientific review that was published in February.

(Gastrointestinal tract. ©Tefi/Shutterstock.com)

Inflammatory bowel disease is associated with arthritis. Research suggests there could be a genetic component or the connection could be associated with an inflamed gut. Learn more here.

(Crohn's disease ©JuanGaertner/Shutterstock.com)

The gold standard for treating Crohn's disease and ulcerative colitis may lie in anti-TNF and anti-integrins therapy, researchers report this week.

Clinical Trial (©GustavoFrazao/Shutterstock.com)

A British study finds that rituximab is "neither clinically or cost-effective" in a study of patients with primary Sjogren’s syndrome who were being treated for fatigue and oral dryness.


By clicking Accept, you agree to become a member of the UBM Medica Community.